Cargando…

Validation of transgenic mice carrying the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing.

Carcinogenicity testing is indispensable for identifying environmental carcinogens and for evaluating the safety of drugs in the process of development. Conventional 2-year rodent bioassays are one of the most resource-consuming tests in terms of animals, time, and costs. Development of rapid carcin...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamamoto, S, Urano, K, Koizumi, H, Wakana, S, Hioki, K, Mitsumori, K, Kurokawa, Y, Hayashi, Y, Nomura, T
Formato: Texto
Lenguaje:English
Publicado: 1998
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1533281/
https://www.ncbi.nlm.nih.gov/pubmed/9539005
_version_ 1782129018577879040
author Yamamoto, S
Urano, K
Koizumi, H
Wakana, S
Hioki, K
Mitsumori, K
Kurokawa, Y
Hayashi, Y
Nomura, T
author_facet Yamamoto, S
Urano, K
Koizumi, H
Wakana, S
Hioki, K
Mitsumori, K
Kurokawa, Y
Hayashi, Y
Nomura, T
author_sort Yamamoto, S
collection PubMed
description Carcinogenicity testing is indispensable for identifying environmental carcinogens and for evaluating the safety of drugs in the process of development. Conventional 2-year rodent bioassays are one of the most resource-consuming tests in terms of animals, time, and costs. Development of rapid carcinogenicity testing systems that can assess carcinogenicity within a short period has become a social demand and is essential to improve efficacy in the identification of environmental carcinogens as well as in the development of new drugs. In this review we introduce the rapid carcinogenicity testing system using transgenic (Tg) mice carrying the human prototype c-Ha-ras gene, namely rasH2 mouse (CB6F1-TgHras2 mouse is the same mouse). The studies have been conducted to validate the rasH2 mouse as a model for the rapid carcinogenicity testing system. Our current validation studies revealed that rasH2 mice are able to detect various types of mutagenic carcinogens within 6 months. The rasH2 mice may also be able to detect various nonmutagenic carcinogens. The validation studies also revealed that rasH2 mice are generally much more susceptible to both mutagenic and nonmutagenic carcinogens than control non-Tg mice. No significant tumor induction has been observed in rasH2 mice with either mutagenic or nonmutagenic noncarcinogens. More rapid onset and higher incidence of more malignant tumors can be expected with a high probability after treatment with various carcinogens in the rasH2 mice than in control non-Tg mice. The rasH2 mouse appears to be a promising candidate as an animal model for development of a rapid carcinogenicity testing system.
format Text
id pubmed-1533281
institution National Center for Biotechnology Information
language English
publishDate 1998
record_format MEDLINE/PubMed
spelling pubmed-15332812006-08-08 Validation of transgenic mice carrying the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing. Yamamoto, S Urano, K Koizumi, H Wakana, S Hioki, K Mitsumori, K Kurokawa, Y Hayashi, Y Nomura, T Environ Health Perspect Research Article Carcinogenicity testing is indispensable for identifying environmental carcinogens and for evaluating the safety of drugs in the process of development. Conventional 2-year rodent bioassays are one of the most resource-consuming tests in terms of animals, time, and costs. Development of rapid carcinogenicity testing systems that can assess carcinogenicity within a short period has become a social demand and is essential to improve efficacy in the identification of environmental carcinogens as well as in the development of new drugs. In this review we introduce the rapid carcinogenicity testing system using transgenic (Tg) mice carrying the human prototype c-Ha-ras gene, namely rasH2 mouse (CB6F1-TgHras2 mouse is the same mouse). The studies have been conducted to validate the rasH2 mouse as a model for the rapid carcinogenicity testing system. Our current validation studies revealed that rasH2 mice are able to detect various types of mutagenic carcinogens within 6 months. The rasH2 mice may also be able to detect various nonmutagenic carcinogens. The validation studies also revealed that rasH2 mice are generally much more susceptible to both mutagenic and nonmutagenic carcinogens than control non-Tg mice. No significant tumor induction has been observed in rasH2 mice with either mutagenic or nonmutagenic noncarcinogens. More rapid onset and higher incidence of more malignant tumors can be expected with a high probability after treatment with various carcinogens in the rasH2 mice than in control non-Tg mice. The rasH2 mouse appears to be a promising candidate as an animal model for development of a rapid carcinogenicity testing system. 1998-02 /pmc/articles/PMC1533281/ /pubmed/9539005 Text en
spellingShingle Research Article
Yamamoto, S
Urano, K
Koizumi, H
Wakana, S
Hioki, K
Mitsumori, K
Kurokawa, Y
Hayashi, Y
Nomura, T
Validation of transgenic mice carrying the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing.
title Validation of transgenic mice carrying the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing.
title_full Validation of transgenic mice carrying the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing.
title_fullStr Validation of transgenic mice carrying the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing.
title_full_unstemmed Validation of transgenic mice carrying the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing.
title_short Validation of transgenic mice carrying the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing.
title_sort validation of transgenic mice carrying the human prototype c-ha-ras gene as a bioassay model for rapid carcinogenicity testing.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1533281/
https://www.ncbi.nlm.nih.gov/pubmed/9539005
work_keys_str_mv AT yamamotos validationoftransgenicmicecarryingthehumanprototypecharasgeneasabioassaymodelforrapidcarcinogenicitytesting
AT uranok validationoftransgenicmicecarryingthehumanprototypecharasgeneasabioassaymodelforrapidcarcinogenicitytesting
AT koizumih validationoftransgenicmicecarryingthehumanprototypecharasgeneasabioassaymodelforrapidcarcinogenicitytesting
AT wakanas validationoftransgenicmicecarryingthehumanprototypecharasgeneasabioassaymodelforrapidcarcinogenicitytesting
AT hiokik validationoftransgenicmicecarryingthehumanprototypecharasgeneasabioassaymodelforrapidcarcinogenicitytesting
AT mitsumorik validationoftransgenicmicecarryingthehumanprototypecharasgeneasabioassaymodelforrapidcarcinogenicitytesting
AT kurokaway validationoftransgenicmicecarryingthehumanprototypecharasgeneasabioassaymodelforrapidcarcinogenicitytesting
AT hayashiy validationoftransgenicmicecarryingthehumanprototypecharasgeneasabioassaymodelforrapidcarcinogenicitytesting
AT nomurat validationoftransgenicmicecarryingthehumanprototypecharasgeneasabioassaymodelforrapidcarcinogenicitytesting